Caris Life Sciences, Inc. (CAI) stock
CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.94−1.06 (-5.05%)
Close on Nov 17, 2026Market cap $5.63BP/E –Yield –
Caris Life Sciences cash
Cash and short-term investments held at the end of each period.
Caris Life Sciences's cash was $822.22M at Mar 31, 2026. For fiscal 2025 it was $798.57M, up 1107.2% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $798.57M | +1107.2% |
| FY2024 | Dec 31, 2024 | $66.15M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $822.22M | +2535.2% |
| Q4 FY2025 | Dec 31, 2025 | $798.57M | +1107.2% |
| Q3 FY2025 | Sep 30, 2025 | $755.49M | – |
| Q2 FY2025 | Jun 30, 2025 | $721.18M | – |
| Q1 FY2025 | Mar 31, 2025 | $31.20M | – |
| Q4 FY2024 | Dec 31, 2024 | $66.15M | – |
See a number that looks wrong?